Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer

Men who develop metastatic castration-resistant prostate cancer (CRPC) invariably succumb to the disease. The development and progression to CRPC following androgen ablation therapy is predominantly driven by unregulated androgen receptor (AR) signaling(1-3). Despite the success of recently approved...

Descripción completa

Detalles Bibliográficos
Autores principales: Asangani, Irfan A., Dommeti, Vijaya L., Wang, Xiaoju, Malik, Rohit, Cieslik, Marcin, Yang, Rendong, Escara-Wilke, June, Wilder-Romans, Kari, Dhanireddy, Sudheer, Engelke, Carl, Iyer, Mathew K., Jing, Xiaojun, Wu, Yi-Mi, Cao, Xuhong, Qin, Zhaohui S., Wang, Shaomeng, Feng, Felix Y., Chinnaiyan, Arul M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075966/
https://www.ncbi.nlm.nih.gov/pubmed/24759320
http://dx.doi.org/10.1038/nature13229

Ejemplares similares

Ejemplares similares